– UK, Bridgend – ReNeuron Group plc (LON: RENE), a UK-based leader in stem cell-derived exosome technologies, announced the appointment of Board member Iain Ross as Executive Chairman following the resignation of Catherine Isted from her CEO role with immediate effect.
“We are excited about the future of the Company and are very grateful to Iain for agreeing to lead the Company going forward. He is an experienced industry executive who has led several successful biotech turnarounds, including more recently that of Redx Pharma plc and Silence Therapeutics plc,” said Senior Independent Director, Barbara Staehelin.
About ReNeuron
ReNeuron is a UK-basedCell-derived Proprietary Stem Cell-derived Exosome Technologies company, harnessing its unique stem cell technologies to develop ‘off the shelf’ treatments for diseases with significant unmet needs.
ReNeuron’s stem cell-derived proprietary Exosome Technology platform offers a delivery mechanism for a variety of payloads such as siRNA, mRNA, proteins, small molecules, and genes. The Company has many partner collaborations with Global Pharma, Biotech, and academic partners in this fast-expanding area of scientific and commercial interest. ReNeuron also has the ability, through its conditionally immortalized induced pluripotent stem cell platform, to make allogeneic tissue cells of choice and has the potential to produce exosomes with tissue-specific targeting ability.
For more information: https://www.reneuron.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
